Personal information

No personal information available

Activities

Collapse all

Works (3)

Optimal Duration of Maintenance Checkpoint Inhibitor Therapy in Patients With Advanced NSCLC

JCO Oncology Practice
2021-08 | Journal article
DOI: 10.1200/OP.21.00059
Contributors: Nikhil Shukla; Nasser Hanna; Greg Durm
Source: check_circle
Crossref

Association of Immune-Related Adverse Events and Efficacy Outcomes with Consolidation Pembrolizumab after Chemoradiation in Patients with Inoperable Stage III Non-small Cell Lung Cancer.

Clinical Lung Cancer
2021-01 | Journal article
DOI: 10.1016/j.cllc.2020.12.014
Contributors: Nikhil Shukla; Sandra Althouse; Zachary Meyer; Nasser Hanna; Greg Durm
Source: check_circle
Crossref

The Story of Angiogenesis Inhibitors in Non–small-cell Lung Cancer: The Past, Present, and Future

Clinical Lung Cancer
2020-07 | Journal article
DOI: 10.1016/j.cllc.2020.02.024
Contributors: Nikhil Atul Shukla; Melissa Noela Yan; Nasser Hanna
Source: check_circle
Crossref
How many people are using ORCID?